Research programme: Nrf2 activators - Cureveda/GlaxoSmithKline

Drug Profile

Research programme: Nrf2 activators - Cureveda/GlaxoSmithKline

Alternative Names: VEDA-1209

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Cureveda; GlaxoSmithKline
  • Developer Cureveda; Georgia State University; GlaxoSmithKline; Johns Hopkins University; Temple University
  • Class Small molecules
  • Mechanism of Action NF E2 related factor 2 stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Chronic obstructive pulmonary disease; Multiple sclerosis; Radiation injuries; Ulcerative colitis

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Ulcerative-colitis in USA
  • 04 Nov 2017 No recent reports of development identified for research development in Multiple-sclerosis in USA
  • 04 Nov 2017 No recent reports of development identified for research development in Radiation-injuries in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top